polygeline: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
polygeline: clinical details
Prescribing considerations
- Individualise administration to haemodynamic status and response.
- Assess risks of intravascular expansion, interstitial fluid accumulation and haemodilution.
- Consider allergy history, recent exposure to histamine-releasing medicines, and electrolyte or calcium exposure where relevant.
Contraindications and cautions
- Known hypersensitivity to polygeline or another constituent
- Existing anaphylactoid reaction
Monitoring
- Observe for hypersensitivity during and after infusion.
- Monitor haemodynamic response, urine output, and pulmonary or peripheral fluid overload.
- Consider haemodilution and haematocrit during substantial blood loss.
Clinical pharmacology
Polygeline is a gelatin derivative. It is iso-oncotic with plasma, is broken down into peptides and amino acids, and has substantial renal elimination.
Formulation and product differences
- The selected product contains calcium, sodium and potassium ions.
- It contains no preservative; discard unused solution after opening.
polygeline interactions
Relevant interactions and compatibility issues include:
Cardiac glycosides, including digoxin
Polygeline contains calcium ions, which may increase cardiac glycoside effects or toxicity.
Histamine-releasing medicines, including some anaesthetics, muscle relaxants, analgesics and anticholinergics
Combined exposure may increase the likelihood of histamine-mediated infusion reactions.
Citrated blood
Do not mix directly with polygeline because its calcium content may cause clotting. Sequential administration requires adequate line flushing.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.